LGALS1 and stroke disorder: The results demonstrate that transplantation of engineered NSCs, especially those that produce gal-1 with a secretory sequence, conferred robust neuroprotection against stroke by decreasing infarct volume, ameliorating white matter injury, and improving sensorimotor and cognitive functions for at least 28 days after stroke.